Advances in Immunotherapy of Cancer

Cancer continues to be a leading cause of morbidity and mortality worldwide, making it crucial to develop more efficient, specific, and durable therapeutic options. Conventional treatment options, including surgery, chemotherapy, and radiotherapy, have demonstrated significant clinical efficacy; however, tumor recurrence, innate and acquired resistance, toxic side effects, and damage to normal tissues limit their clinical implementation. The cancer-immunity cycle is a newly described series of events that involve the immune system and are necessary for an effective anti-tumor immune response. The process starts with the release of neoantigens from dying tumor cells via immunogenic cell death. Dendritic cells and other antigen-presenting cells (APCs) receive tumor-associated antigens, which are then presented to naïve T lymphocytes in the lymph nodes. Consequently, cancer immunotherapy has emerged as a promising strategy to fight tumors by stimulating and enhancing endogenous anti-cancer immune responses. The cancer immunotherapy area has undergone a paradigm shift from non-specific to tailored and precise treatments. Immune checkpoint inhibitors targeting programmed cell death protein-1 (PD-1) and programmed death-ligand 1 (PD-L1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) have significantly improved the overall survival of patients with various tumor types. Chimeric antigen receptor (CAR) T-cell therapy, which involves genetic modification of the patient's T cells to bind to specific tumor-associated antigens, has also enhanced cancer treatment options. Cancer vaccines, monoclonal antibodies, bispecific antibodies, cytokines, and oncolytic viruses are other effective cancer immunotherapy options that have shown promising preclinical and clinical results. Current research is focused on combination immunotherapy, personalized cancer vaccines, biomarker-driven approaches, and novel cell-based cancer treatments, including updated versions of CAR T cells and T-cell receptor (TCR) therapies. Nevertheless, major therapeutic challenges, including immune-related toxicities, tumor heterogeneity and antigen variability, innate and acquired resistance, and cost, hinder the widespread application of immunotherapy. Further understanding of tumor immunology, genetic engineering, and precision medicine will improve cancer immunotherapy and patient outcomes. Combination immunotherapy is a powerful approach to increase therapeutic efficacy and overcome tumor resistance.